{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Vanda Pharmaceuticals Inc."},"Symbol":{"label":"Symbol","value":"VNDA"},"Address":{"label":"Address","value":"2200 PENNSYLVANIA AVENUE NW,SUITE 300 E, WASHINGTON, District of Columbia, 20037, United States"},"Phone":{"label":"Phone","value":"+1 202 734-3400"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improves the lives of patients. Its commercial portfolio comprises two products, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) and nighttime sleep disturbances in Smith-Magenis Syndrome (SMS) and Fanapt for the treatment of schizophrenia. Its other products include Tradipitant (VLY-686), VTR-297, and VQW-765."},"CompanyUrl":{"label":"Company Url","value":"https://www.vandapharma.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Mihael Hristos Polymeropoulos","title":"Chairman, President & Chief Executive Officer"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}